Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Tempus Wealth Planning LLC

Tempus Wealth Planning LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,903 shares of the biopharmaceutical company’s stock after selling 745 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Bristol-Myers Squibb were worth $843,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Calamos Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 2.5% in the fourth quarter. Calamos Wealth Management LLC now owns 11,123 shares of the biopharmaceutical company’s stock valued at $629,000 after acquiring an additional 270 shares in the last quarter. Trust Point Inc. boosted its stake in Bristol-Myers Squibb by 1.9% during the 4th quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company’s stock worth $533,000 after purchasing an additional 172 shares during the period. Childress Capital Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 17.6% in the 4th quarter. Childress Capital Advisors LLC now owns 7,018 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 1,051 shares during the last quarter. F&V Capital Management LLC raised its position in Bristol-Myers Squibb by 0.9% during the 4th quarter. F&V Capital Management LLC now owns 172,158 shares of the biopharmaceutical company’s stock worth $9,737,000 after buying an additional 1,600 shares during the last quarter. Finally, GEN Financial Management INC. acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $222,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research analyst reports. Bank of America reaffirmed a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $56.60.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $60.03 on Tuesday. The company has a market cap of $121.76 billion, a P/E ratio of -16.72, a PEG ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The business has a 50 day moving average of $57.60 and a two-hundred day moving average of $53.34.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.13%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.